Limited Asian Fallout From Pfizer-Allergan Merger?
This article was originally published in PharmAsia News
As far as Asian and emerging pharma markets go, it is clear that Pfizer will be the dominant partner in the planned $160bn merger with Allergan. The US firm has a broad reach in these areas that Allergan will be looking to tap into, and major restructuring in big regional markets such as China and Japan looks unlikely.
Register for our free email digests: